A Systematic Review – Does Local Treatment of the Prostate in Advanced and/or Lymph Node Metastatic Disease Improve Efficacy of Androgen-Deprivation Therapy?

One of the largest and most controversial issues for the treatment of advanced prostate cancer is the value of androgen-deprivation therapy (ADT). Most doctors use ADT as their pivotal initial treatment in the management of locally advanced and metastatic prostate cancer (PCa). But, the grand question is does it extend survival? […]

Have You Experienced Therapeutic Drug Switching?

Have you had the experience of being given a different medication from the pharmacy than was prescribed by your doctor? Have you had the pharmacy switch your prescription, whether from a brand to a generic or to a different generic, or even to a different class of medication altogether? If you know of anybody who [...]

A Take Away Point from the Last American Urological Association (AUA) Meeting

The prognosis of patients with advanced prostate cancer who have lymph node metastasis depends on the number of positive lymph nodes removed and Gleason score of the primary tumor. Bilateral pelvic lymph node dissection should be performed in intermediate- and high-risk patients to identify those with minimal nodal burden who may benefit the most from [...]

Carboplatin plus Paclitaxel Therapy after Docetaxel in Men with Metastatic Castrate Resistant Prostate Cancer

UroToday.com published a dual-center study today that confirms that carboplatin and paclitaxel (a taxane product) has an active effect on PSA when used in the treatment of men with castrate resistant prostate cancer (CRPC) after docetaxel (chemotherapy for prostate cancer). […]

Go to Top